Author

Isaac Prah

Mayo Clinic in FloridaORCID 0000-0001-6087-0604Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Isaac Prah1 paper · Texas A&M Health Science Center

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:C. elegans· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:GWAS / association mapping· 1 Assay:GWAS summary statistics· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metagenomics· 1

Frequent Co-Authors

Anthony C. LuehrsiD· 1 shared Chadi AyoubiD· 1 shared Chetna DurejaiD· 1 shared Dianqing SuniD· 1 shared Fahad Bin Aziz Pavel· 1 shared Hector R. VillarragaiD· 1 shared Hugues SicotteiD· 1 shared Jacob T. RutherfordiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Anthony C. LuehrsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicineCirculation Genomic and Precision MedicinePeer-reviewedJul 29, 2026

Meta-analysis of genome-wide association studies of doxorubicin-induced arrhythmia identifies MMP16 and KCTD15 as risk loci

Joseph S. Reddy, Milagros Pereyra, Mohammed Tiseer Abbas…·Nadine Norton

This study identifies genetic risk loci for doxorubicin-induced arrhythmia through GWAS meta-analysis and validates their functional relevance in human and zebrafish models.

DOI 10.1161/circgen.125.005651

𝕏 PostBluesky

MicrobiologyAntimicrobial Agents and ChemotherapyPeer-reviewedJan 24, 2024

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

Chetna Dureja, Jacob T. Rutherford, Fahad Bin Aziz Pavel…·Julian Gregston Hurdle

This study evaluates the in vivo efficacy of phenylimidazole 296 against C. difficile by targeting CdFabK, showing it retains microbiome stability better than vancomycin and fidaxomicin.

5 citations

C. elegansmouse

𝕏 PostBluesky